310 related articles for article (PubMed ID: 7178872)
1. [Bioavailability of 3 theophylline delayed-release preparations. Comparison of theophylline concentrations in the serum and saliva in the steady state].
Bochsler HP; Meyer UA
Schweiz Med Wochenschr; 1982 Nov; 112(47):1702-10. PubMed ID: 7178872
[TBL] [Abstract][Full Text] [Related]
2. Comparison of steady state serum theophylline concentrations in healthy volunteers after dosing with Euphyllin retard and PulmiDur.
Karlsson S; Lührmann B; Bahner ML; Schulz HU
Int J Clin Pharmacol Ther Toxicol; 1987 Jun; 25(6):342-6. PubMed ID: 3623739
[TBL] [Abstract][Full Text] [Related]
3. Bioavailability of theophylline from a sustained-release aminophylline formulation (Euphyllin retard tablets)--plasma levels after single and multiple oral doses.
Schuppan D; Molz KH; Staib AH; Rietbrock N
Int J Clin Pharmacol Ther Toxicol; 1981 May; 19(5):223-7. PubMed ID: 7251238
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamics of three sustained-release theophylline preparations (350 mg Theograd, 350 mg Theolair Retard and 300 mg Theodur) in steady state in healthy volunteers and asthmatics--Part I: Theophylline plasma levels.
van der Vet AP; Drost RH; Kreukniet J; Maes RA
Int J Clin Pharmacol Ther Toxicol; 1984 Aug; 22(8):423-9. PubMed ID: 6490224
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic properties of a new sustained-release theophylline preparation.
Dahlqvist R; Billing B
Int J Clin Pharmacol Ther Toxicol; 1983 Feb; 21(2):69-72. PubMed ID: 6840927
[TBL] [Abstract][Full Text] [Related]
6. Study of bioavailability and pharmacokinetics of theophylline following administration of two sustained release dosage forms as assessed by salivary data: Part II.
Ohmori N; Inotsume N; Matsukura M; Higashi A; Iwaoku R; Tobino Y; Nakano M; Matsuda I
Int J Clin Pharmacol Ther Toxicol; 1986 Apr; 24(4):196-201. PubMed ID: 3710632
[TBL] [Abstract][Full Text] [Related]
7. Absorption of sustained-release theophylline tablets.
Fagerström PO; Heintz L
Int J Clin Pharmacol Ther Toxicol; 1983 Jul; 21(7):359-62. PubMed ID: 6885207
[TBL] [Abstract][Full Text] [Related]
8. Bioavailability of sustained-release theophylline formulations.
Bonora Regazzi M; Rondanelli R; Vidale E; Cristiani D
Int J Clin Pharmacol Ther Toxicol; 1983 May; 21(5):245-51. PubMed ID: 6862729
[TBL] [Abstract][Full Text] [Related]
9. Comparison of aminophylline and theophylline sustained-release formulations by their bioavailability and steady-state serum levels.
Steinijans VW; Zech K; Fischer R
Int J Clin Pharmacol Ther Toxicol; 1983 Dec; 21(12):624-30. PubMed ID: 6668100
[TBL] [Abstract][Full Text] [Related]
10. Influence of food on steady state serum concentrations of theophylline from two controlled-release preparations.
Lefebvre RA; Belpaire FM; Bogaert MG
Int J Clin Pharmacol Ther Toxicol; 1988 Aug; 26(8):375-9. PubMed ID: 3220610
[TBL] [Abstract][Full Text] [Related]
11. [Absolute bioavailability of theophylline (Euphylline)].
Somogyi A; Gugler R
Fortschr Med; 1980 Nov; 98(43):1707-10. PubMed ID: 7450653
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacokinetics and biologic availability of a new theophylline sustained-release preparation].
Brüller W; Fischer M; Tritthart W
Arzneimittelforschung; 1985; 35(12):1854-9. PubMed ID: 4096745
[TBL] [Abstract][Full Text] [Related]
13. Comparative pharmacokinetic analysis of theophylline in serum and saliva.
Trnavská Z; Rejholec V; Elis J; Spicák V
Int J Clin Pharmacol Res; 1987; 7(5):329-35. PubMed ID: 3667005
[TBL] [Abstract][Full Text] [Related]
14. The relation of product formulation to absorption of oral theophylline.
Weinberger M; Hendeles L; Bighley L
N Engl J Med; 1978 Oct; 299(16):852-7. PubMed ID: 692577
[TBL] [Abstract][Full Text] [Related]
15. Monitoring of theophylline treatment by saliva and plasma concentrations.
Juntunen-Backman K; Backman A; Björkstén F; Finnilä MJ
Allergol Immunopathol (Madr); 1988; 16(1):5-9. PubMed ID: 3381714
[TBL] [Abstract][Full Text] [Related]
16. [Absorption profile and absolute bioavailability of a theophylline sustained-release preparation].
Pabst G; Weber W; Barkworth MF; Müller M; Rehm KD
Arzneimittelforschung; 1998 May; 48(5A):574-9. PubMed ID: 9676347
[TBL] [Abstract][Full Text] [Related]
17. [Absorption profile and absolute bioavailability of a theophylline--retard preparation].
Pabst G; Weber W; Barkworth MF; Müller M; Rehm KD
Arzneimittelforschung; 1990 Nov; 40(11):1218-24. PubMed ID: 2085333
[TBL] [Abstract][Full Text] [Related]
18. The relationship between pharmacodynamics and pharmacokinetics in asthmatic children receiving a sustained-release formulation of theophylline.
Schaefers M; Richter O; Reinhardt D; Becker B
Int J Clin Pharmacol Ther Toxicol; 1984 Aug; 22(8):406-15. PubMed ID: 6490223
[TBL] [Abstract][Full Text] [Related]
19. [Bioavailability of theophylline in a new oral sustained-release preparation (author's transl)].
Schneider GF; Heese GU; Huber HJ; Janzen N; Jünger H; Moser C; Stanislaus F
Arzneimittelforschung; 1981; 31(9):1489-97. PubMed ID: 7197962
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacokinetic and therapeutic monitoring in the development of theophylline-retard preparations].
Iwainsky H; Wilke A; Weide W; Schäfer K
Pharmazie; 1987 Apr; 42(4):242-4. PubMed ID: 3615555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
